HIF1A and breast cancer: Oroxylin A reduced HIF-1 stability and activity in a MDA-MB-231 cells by boosting the production of the destabilizing enzyme inhibitory protein 3, consequently reducing HIF-1 expression in breast cancer cells (Wei et al., 2015).